3629 results for «302»

Filter By

3629 results

How should I treat a blue baby - A patient's journey

03 Mar 2023 – From AfricaPCR 2023

Consider the very specific case of a female newborn whose predictive diagnosis suggested two leads: newborn transient tachypnea vs neonatal sepsis, and analyze how this little patient was managed, from birth to final treatment.

How should I treat a blue baby - A patient's journey

Anterograde LAD CTO - LIVE case

03 Mar 2023 – From AfricaPCR 2023

A 66-year-old male presented an ACS two months ago with MVD, preserved LV function without regional wall abnormality. The medical team decided to address this condition with a double PCI: one in the mid-RCA and another in the distal CX. Their plan includes performing PCI of the LAD CTO.
During the procedure, the operators...

CTO: LIVE case from Sunninghill

Bifurcation and CTO clinical cases

03 Mar 2023 – From AfricaPCR 2023

This session presents several challenging clinical cases including an in-stent restenosis in a bifurcation and retained wire, a left main thrombus, and an open CTO for retrograde approach of another CTO. Watch now to find out more!

Bifurcation and CTO clinical cases

Efficacy and safety of Edoxaban in anticoagulant therapy early after surgical bioprosthetic valve replacement: ENBALV trial

16 Nov 2024

Edoardo Zancanaro provides his take on the ENBALV trial presented by Chisato Izumi at AHA 2024 in Chicago.

Edoardo Zancanaro

Author

Edoardo Zancanaro
ENBALV

Clinical implementation of clopidogrel pharmacogenetics: the Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI) Trial

01 Apr 2020

A genotype-guided oral P2Y12 inhibitor strategy compared with conventional clopidogrel therapy with point-of-care genotyping in CYP2C19 LOF patients with ACS and stable CAD undergoing PCI resulted in a no significant reduction in ischemic events at 12-months.

Luis Ortega-Paz

Author

Luis Ortega-Paz
Clinical implementation of clopidogrel pharmacogenetics: The Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI) Trial

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

Transcatheter edge-to-edge repair of functional mitral regurgitation in heart failure: Final five-year results from the COAPT Trial

06 Mar 2023

Alex Sticchi & Jonathan Curio provide their take on the clinical trial presented by Gregg W. Stone at the American College of Cardiology Scientific Sessions (ACC.23/WCC).

Jonathan Curio

Author

Jonathan Curio
Alessandro Sticchi

Author

Alessandro Sticchi
Transcatheter edge-to-edge repair of functional mitral regurgitation in heart failure: Final five-year results from the COAPT Trial

ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation

31 Aug 2021

Following the Hot Line session of the ESC Congress 2021 presented by George Dangas (New-York, USA), Daniele Giacoppo offers us a condensed version of this study.

Daniele Giacoppo

Author

Daniele Giacoppo
ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!

17 Oct 2020

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Author

Hector Garcia
Live from TCT Connect 2020: PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB
Didn’t find what you were looking for?